Chignolo D’Isola, Bergamo, Italy – November 1, 2021 – Flamma SpA (“Flamma”), a
preeminent Contract Development and Manufacturing Organization (CDMO) that develops,
manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs)
for the pharmaceutical industry, proudly announces that Flamma Honkai has passed its final
inspection by the Chinese National Medical Products Administration (NMPA) formally known
as the Chinese FDA.
This milestone marks Flamma’s ongoing efforts to continue to bring significant value and
trust from its customer base.
“The effort by not only the Flamma Honkai team but the entire Flamma team is a testament
to our desire to provide the type of quality that is expected at every Flamma site”, said
Kenneth Drew, Ph.D., VP Flamma USA. “Many people are understandably worried about
working in China. Flamma has long maintained that we have many Italian sites but one
happens to be located in China. Our attention to customer needs helps to set us apart from
other CDMOs.”
Flamma is looking to expand our footprint within China and will be moving towards another
workshop in the Songmudao Chemical Park in the province of Liaoning. While chemical
parks located near Beijing & Shanghai are facing heavy environmental scrutiny & random
chemical park closures, being located away from these areas as well as being in a special
chemical park located outside of the city of Dalian provides a sense of stability and security.
Flamma Honkai can help companies looking to manufacture APIs within China for the
Chinese marketplace. Companies can also take advantage of our Italian sites for APIs as
well making Flamma unique within the industry.
For further information, please visit the Flamma website at http://www.flammagroup.com.
Contact Flamma
Kenneth Drew, Ph.D., VP Flamma USA
1-617-515-0975
ken.drew@flammagroup.com
About Flamma:
FLAMMA is a family owned & run, fully integrated CMO based in Bergamo (near Milan in
Northern Italy) established in 1950.
FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs, and
advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in
high value chiral materials specifically amino acid related materials. Flamma also
manufactures specialty compounds and advanced intermediates for the nutraceutical and
cosmetic industries and has several generic products.
FLAMMA has four manufacturing facilities all with R&D labs- Italy (2), China, and the USA.
Both cGMP Italian locations (Chignolo & Isso) are regularly inspected by the FDA and AIFA.
Flamma Honkai, located in Dalian, China, has a new R&D building as well as a cGMP
production plant. Flamma provides security when working in China with our 100% owned,
self-managed facilities that deliver results without worry. Flamma reliably supplies materials
directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver
the customer’s compound on-time and with the desired specifications. Flamma offers costeffective
services to customers looking for a trusted partner within China.
Flamma USA is located outside Philadelphia provides Flamma with the ability to service
customers looking to keep materials in the USA for pre-clinical/early stage clinical
development.
Being a fully integrated company allows Flamma to move your compounds quickly along their
journey taking into consideration all aspects necessary for the success of your project.
Flamma can be of assistance for early stage pre-clinical development of small molecules as
well as for large-scale commercial manufacturing. With a total reactor capacity of 450 m3 and
over 600 employees, see why Flamma should be your next contract manufacturer. FLAMMA
– THE THINKING CDMOTM.
For more information, please visit www.flammagroup.com
https://www.flamamgroup.com/
https://www.linkedin.com/company/flamma-spa/
https://twitter.com/flammagroup
https://www.facebook.com/TheFlammaGroup
